152 related articles for article (PubMed ID: 23934862)
1. PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness.
Ahrens MJ; Bertin PA; Vonesh EF; Meade TJ; Catalona WJ; Georganopoulou D
Prostate; 2013 Dec; 73(16):1731-7. PubMed ID: 23934862
[TBL] [Abstract][Full Text] [Related]
2. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
3. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
4. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
5. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
8. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
10. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
11. Performance characteristics of prostate-specific antigen in patients undergoing radical prostatectomy.
Liu JJ; Ferrari M; Nolley R; Brooks JD; Presti JC
Urology; 2012 Jun; 79(6):1336-9. PubMed ID: 22516358
[TBL] [Abstract][Full Text] [Related]
12. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Witherspoon LR; Lapeyrolerie T
J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
14. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
16. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
18. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
19. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
